Loading...
Median duration of extended adjuvant treatment with neratinib
Median treatment holds and permanent discontinuations time
% of patients with different demographic characteristics
% of patients with different disease characteristics
Median time to treatment since completion of adjuvant regimen
% of patients with different prior adjuvant treatments
% of patients with dose adjustments
Absolute and relative dose intensity
% of patients with different concomitant medications
Incidence of all grades of adverse events of special interest (AESI)
% of different type of all grades of adverse events of special interest (AESI)
% of patients with adverse events by severity
% of patients with action taken against adverse events